Eosinophilic esophagitis (EoE) is a chronic esophageal inflammatory disease of undetermined pathophysiology that results in dense mucosal eosinophilia and esophageal dysfunction. In childhood ...

Eupraxia Pharma reports positive data from RESOLVE phase 1b/2a trial of EP-104GI for treatment of eosinophilic esophagitis: Victoria, British Columbia Thursday, November 14, 2024, ...

The investigational monoclonal antibody cendakimab significantly improved symptoms and reduced esophageal eosinophils in ...

Allergic reactions come in all varieties. One can even trigger a digestive disease called Eosinophilic Esophagitis, which ...

The safety results from the EoE KIDS study were consistent with the known safety profile of Dupixent in adolescents and ...

Citation: Among allergic conditions, food allergy found to have highest risk of developing eosinophilic esophagitis (2024, October 24) retrieved 11 November 2024 from https://medicalxpress.com ...

Dupixent approved in the EU as the first and only medicine for young children with eosinophilic esophagitisApproval based on phase 3 data showing ...

Sanofi (SNY) has released an update. Sanofi’s Dupixent has received EU approval as the first treatment for children aged one to 11 with eosinophilic esophagitis, expanding its market potential ...

EMA approves Dupixent to treat eosinophilic esophagitis in children as young as one year: Paris Thursday, November 7, 2024, 14:00 Hrs [IST] The European Medicines Agency has appro ...

Paris: Sanofi has announced that the European Medicines Agency has approved Dupixent (dupilumab) to treat eosinophilic ...

Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology ...

Nat Clin Pract Gastroenterol Hepatol. 2009;6(5):267-278. A thorough history and assessment of allergic diseases is a vital part of the evaluation of a patient with suspected EoE because of the ...